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Rare diseases are usually defined as entities affecting less than 1 person per 2,000. About 7,000 different rare entities
are distinguished and, among them, rare diseases of the thyroid gland. Although not frequent, they can be found
in the everyday practice of endocrinologists and should be considered in differential diagnosis. Rare non-neoplastic
thyroid diseases will be discussed. Congenital hypothyroidism’s frequency is relatively high and its early treatment is
of vital importance for neonatal psychomotor development; CH is caused primarily by thyroid dysgenesis (85%) or
dyshormonogenesis (10-15%), although secondary defects - hypothalamic and pituitary - can also be found; up to
40% of cases diagnosed on neonatal screening are transient. Inherited abnormalities of thyroid hormone binding
proteins (TBG, TBP and albumin) include alterations in their concentration or affinity for iodothyronines, this leads to
laboratory test abnormalities, although usually with normal free hormones and clinical euthyroidism. Thyroid hormone
resistance is most commonly found in THRB gene mutations and more rarely in THRA mutations; in some cases both
genes are unchanged (non-TR RTH). Recently the term ‘reduced sensitivity to thyroid hormones’ was introduced, which
encompass not only iodothyronine receptor defects but also their defective transmembrane transport or metabolism.
Rare causes of hyperthyroidism are: activating mutations in TSHR or GNAS genes, pituitary adenomas, differentiated
thyroid cancer or gestational trophoblastic disease; congenital hyperthyroidism cases are also seen, although less
frequently than CH. Like other organs and tissues, the thyroid can be affected by different inflammatory and infectious
processes, including tuberculosis and sarcoidosis. In most of the rare thyroid diseases genetic factors play a key role,
many of them can be classified as monogenic disorders. Although there are still some limitations, progress has been
made in our understanding of rare thyroid diseases etiopathogenesis, and, thanks to these studies, also in our
understanding of how normal thyroid gland functions.
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Thyroid hormone resistance, Dysgenesis, Dyshormonogenesis, MutationIntroduction
Rare diseases are usually defined as entities affecting 5
or fewer per 10,000 (1 person per 2,000), although differ-
ent thresholds can also be found, e.g. in Japan - fewer than
4 cases per 10,000 or in the United States - fewer than
200,000 patients affected across the country. Despite this
rarity, the total number of a people with diagnosis of rare
diseases is estimated at 350 million all over the world.
Approximately 7,000 distinct rare entities are described,
most of them genetically determined [1]. Another term -
ultra-rare diseases - is usually referred to diseases that
affect less than 1 person per 50,000 [2].
On the basis of prevalence, some thyroid gland diseases
can also be classified as rare. They have genetic origin in* Correspondence: kktlacka@gmail.com
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article, unless otherwise stated.most cases, often as a result of single gene mutations
(monogenic disorders). Rare thyroid diseases should be
considered in differential diagnosis of commonly seen
thyroid entities, their right diagnosis may be often of vital
importance. The aim of this review is therefore to briefly
present the spectrum of rare thyroid diseases and
underling etiopathogenesis. Rare thyroid diseases can
be classified into two main categories: neoplastic and
non-neoplastic disorders. Rare thyroid non-neoplastic
entities will be discussed further in this paper.Review
Congenital hypothyroidism
Congenital hypothyroidism (CH) can be classified as
primary or secondary. The causes of primary CH are
thyroid dysgenesis or dyshormonogenesis. Secondary CH
may be: 1) hypothalamic (also called tertiary CH) – TRHd Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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with multihormonal insufficiency (some known mutations
of transcription factors’ genes such as Pit 1, Prop 1, LHX
3, LHX 4, HESX1, but 80-90% of idiopathic origin) or iso-
lated TSH deficiency (TSHB or rTRH genes mutations).
Some cases of congenital thyroid hormones deficiency are
transient (the percentage varies between studies, up to
40%) and euthyroidism is achieved within the first months
or years of life (maternal antithyroid drug intake, maternal
TSHR blocking antibodies, iodine deficiency or excess,
some heterozygous mutations of DUOX2 and DUOXA2,
congenital liver hemangioma) [3]. Lack of thyroid hor-
mone action at birth may also result from peripheral
causes (peripheral congenital hypothyroidism), which will
be discussed in subsequent paragraphs.
The general prevalence of CH, regardless of its etiology,
is 1:2,000 to 1:4,000 of neonates (primary CH - 1:4,000,
secondary CH – 1:66,000) with a female-to-male ratio of
2:1. These values vary between different regions (1:800 in
the Greek Cypriot population, 1:2,000 in China, 1:2,300 in
the US and 1:10,000 in France) or ethnic groups (highest
prevalence in Asians) [3-5]. In Poland it is estimated that
CH affects about 1:4,500 of all screened neonates [6]. In
iodine sufficient regions, the vast majority of CH cases are
caused by thyroid dysgenesis (up to 85%) and dyshormo-
nogenesis (10-15%), while secondary CH is responsible for
only 0.0015% of all cases [7]. The genes involved in CH
etiopathogenesis are presented in Figure 1.Figure 1 Genetic background of congenital hypothyroidism.Dysgenesis
The term thyroid dysgenesis includes the ectopic loca-
tion of the gland (thyroid ectopy), absence (athyreosis)
and underdevelopment of the thyroid tissue (hypoplasia).
Unilateral thyroid agenesis (hemiagenesis) is also classi-
fied as thyroid dysgenesis, although usually with clinical
euthyroidism [8]. Within the group of thyroid dysgene-
sis, ectopy is found most commonly, with lingual, supra-
and infrahyoid localization of the gland most frequently
seen. Cases of thyroid dysgenesis are usually sporadic,
inherited genetic defects are only recognized in about
2% of all cases and result from transcription factor genes
mutations (PAX8, NKX2-1/TITF1, NXK2-5, FOXE1/
TITF-2) [9]. As these transcription factors are also in-
volved in extrathyroid development, different organs’
congenital anomalies may coexist (Table 1). The thyroid
gland is the only organ affected by TSHR gene (14q31.1)
mutations, which account for about 1% of all CH cases.
As more than 60 different TSHR loss-of-function muta-
tions have been found (Y444X described for the first
time in the Polish population), a variable degree of TSH
resistance and ongoing clinical presentation are observed
(from euthyroid hyperthyrotropinemia to hypoplasia with
severe hypothyroidism) [10,11]. TSH resistance is also ob-
served in mutations of GNAS gene (20q13.32), encoding
the alpha subunit of G protein, downstream of TSH
receptor in the signaling pathway. As G protein is also
responsible for signal transduction of other peptide
Table 1 Transcription factor genes responsible for thyroid dysgenesis
Gene Locus Type of inheritance Expression Clinical manifestation
PAX8 2q13 AD Thyroid, kidney, CNS Thyroid hypoplasia or athyreosis, agenesis/hemiagenesis
of the kidneys
NKX2-5 5q35.1 AD Thyroid, heart, pharynx Thyroid ectopy, athyreosis, congenital cardiac malformations
FOXE1/TITF2 9q22.33 AR Thyroid, pituitar, tongue, epiglottis,
palate, pharynx, thymus and Rathke’s
pouch, choanae, hair follicles
Athyreosis, other forms of thyroid dysgenesis, cleft palate,
cleft epiglottis, choanal atresia, spiky hair
NKX2-1/TITF1 14q13.3 AD Thyroid, lung, trachea, CNS Thyroid dysgenesis, dyshormonogenesis due to inhibited TG
expression, choreoatetosis, hypotony, respiratory distress
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and the clinical picture is complex (pseudohypopar-
athyroidism type 1a) [12]. The role of environmental
factors (e.g. intrauterine viral infections) in thyroid
dysgenesis is also suggested [13].
Dyshormonogenesis
Another reason for primary CH – dyshormonogenesis –
arises from defective thyroid hormone synthesis; all its
stages may be affected (Figure 2). These monogenic
defects are inherited predominantly with an autosomal
recessive pattern. Clinically, in addition to the symptoms
and signs of thyroid hormone deficiency (rarely euthyr-
oidism), patients may present with goiter.
Mutations in the SLC5A5 gene (19p13.11) encoding
sodium-iodide symporter (NIS) result in a defect in the
active transport of iodide to thyrocytes. NIS glycoprotein
is expressed not only in the thyroid follicular cells, but
also in some non-thyroid tissues – salivary and lacrimalFigure 2 Thyroid hormone biosynthesis (possible genetic defect sitesglands, cancerous breast tissue, the breast during lacta-
tion, the intestines, stomach, testes and placenta. To
data, at least 12 different loss-of-function mutations in
the NIS gene have been described [14]. This relatively
rare cause of dyshormonogenesis is characterized by an
autosomal recessive pattern of inheritance. Diminished
or completely inhibited iodine uptake by the thyroid is
characteristic.
Pendrin, encoded by SLC26A4 gene (7q22.3), is an
anion transporter expressed primarily in the thyroid
(allows iodide efflux into the follicular lumen) but also
in the inner ear, kidneys and lungs. Bi-allelic mutations
of the SLC26A4 gene (about 470 mutations described
to date) lead mainly to two different phenotypes: a)
non-syndromic hearing loos with enlarged vestibular
aqueduct (EVA) or b) Pendred syndrome (PDS) with
congenital bilateral sensorineural hearing loss and thyroid
defect (diffuse or multinodular goiter, thyroid hormone
status is dependent on iodide intake, with dominance ofshown in black).
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rare cause of CH (2-3%), goiter often occurs later, in child-
hood or early adolescence. Patients with PDS are at
increased risk of thyroid cancer development (about 1%),
most likely follicular carcinoma [18].
Thyroid peroxidase (TPO) catalyze iodide oxidation,
tyrosyl residue iodination and their coupling to iodothyro-
nines [19]. TPO (2p25.3) mutation is considered to be the
most prevalent cause of dyshormonogenesis (24-46%),
and is found in about 1:60,000 newborns, with about 90
different mutations already described [15,20]. The disease
is generally inherited with an autosomal recessive manner,
although monoallelic mutations may be a risk factor for
transient hypothyroidism.
In the process of iodothyronine synthesis, H2O2 is
required, which is produced by the dual oxidase enzyme
(DUOX/ThOX). Two variants of DUOX can be distin-
guished, with type 2 being critical for thyroid hormone
synthesis [21]. In the case of DUOX2 (15q21.1), autosomal
dominant mode of inheritance is observed, although ho-
mozygotes are usually affected more severely. Patients
with mono-allelic mutations typically present with transi-
ent congenital hypothyroidism, but should be monitored
in adulthood in situations characterized by an increased
thyroid hormone requirement, such as pregnancy [22].
Defects in another thyroid protein - DUOXA2 (15q21.1),
which is indispensable for DUOX2 maturation and trans-
location, can also cause CH [23].
Thyroglobulin (TG) is essential in thyroid hormone
synthesis as it provides tyrosyl residues and enable the
storage of hormones and iodine. Since it was first
described, more than 50 different mutations that lead to
CH have been found [24]. TG (8q24.22) mutations are
described as one of the most prevalent causes of dyshor-
monogenesis ( 1:67,000 to 1:100,000) [24,25]. A charac-
teristically undetectable or very low TG level is observed
in these patients, T4 concentration is found to be dis-
proportionately lower than T3 (a result of increased
type-2 iodothyronine deiodinase activity) [26].
Although the end products of hormonogenesis are T3
and T4, most iodine particles are embedded to mono-
and diiodotyronines (MIT, DIT). Reuse of this iodine is
possible due to MIT and DIT deiodination by an iodo-
tyrosine deiodinase (IYD). Mutations in the IYD gene
(6q25.1) may lead to goitrous hypothyroidism [27]. A
characteristic feature is excessive urinary and blood MIT
and DIT concentrations [28].
Inherited thyroid hormone binding protein abnormalities
TBG
Thyroxin binding globulin (TBG) is the main protein
that binds T3 and T4 in the blood (70% and 70-80% re-
spectively); other transporting particles (transthyretin
and albumin) play a minor role. TBG is encoded by theSerpina 7 gene (Xq22.3) and expressed in the liver [29].
Three different congenital TBG abnormalities are distin-
guished according to its concentration: complete defi-
ciency (TBG-CD), partial deficiency (TBG-PD) and excess
(TBG-E). They are inherited in a X-linked recessive pat-
tern (although a case of autosomal dominant inheritance
of TBG-PD has been described) [30]. There are also some
TBG polymorphic variants that do not alter the protein
concentration.
TBG-CD is diagnosed when the protein level is un-
detectable by typically used assays (or is lower than
0.03% of the normal mean value), and can be found in
hemizygous men and homozygous women. Heterozy-
gous women usually have only a slightly diminished
TBG concentration (carriers), although rarely, as a result
of selective X chromosome inactivation, TBG-CD may
develop [31]. Men with TBG-PD have a significantly de-
creased serum concentration of globulin, while women
are found to have values that may even overlap the nor-
mal range. TBG deficiency is estimated to occur in
1:15,000 to 1:5,000 of all newborns in the Caucasian
population (there is a higher frequency in the Japanese
population), with TBG-CD in one-third of them [32]. At
least 22 different TBG-CD and 8 TBG-PD mutations
have been described (TBG-CD mutations shown on
Figure 3) [33]. Laboratory tests in these generally euthyr-
oid patients show normal TSH, fT3 and fT4 with a low
T4, T3 and undetectable TBG level.
Excessive TBG concentration is typically observed in
the course of elevated estrogen level (e.g. pregnancy).
Congenital TBG-E occurs rarely, as a consequence of
gene duplication or triplication (in 1:6,000 to 1:40,000 of
all newborns) [34]. In such cases, the values measured
are 2–3 times higher than normal in men and mildly ele-
vated in heterozygous women [35].
TTR
About 20% of T4 and 10-20% of T3 is bound in serum
by transthyretin (TTR)/thyroxine binding prealbumin
(TBPA), a homotetrameric protein synthetized in the
liver. Over 120 different disease-associated mutations
have been found in TTR gene (18q12.1), with variable
manifestation. Most commonly they lead to amyloid de-
position in the cardiac tissue and/or peripheral nerves,
without affecting the status of thyroid hormones [15,36].
There is also a group of mutations that lead to a consider-
ably increased affinity for iodothyronines (predominantly
T4) and may result in euthyroid dysprealbuminemic
hyperthyroxinemia with an elevated serum total T4, rT3
and fT4 index (TSH, fT4, T3 and fT3 unaffected) [37].
Dysprealbuminemic hyperthyroxinemia is transmitted in
an autosomal dominant manner and accounts for approxi-
mately 2% of all euthyroid hyperthyroxinemia cases [38].
Mutations associated with an increased concentration of
Figure 3 Mutations responsible for TBG-CD (mutations in coding regions shown in white boxes, mutations in non-coding regions
shown in grey boxes) [70-83].
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served augmentation in the protein level is not high
enough (although in the course of some malignancies e.g.
hepatocellular carcinoma, the TTR concentration may in-
crease significantly and bring about the picture of euthyr-
oid hyperthyroxinemia) [39]. Some of the TTR mutations
lead to a decrease in protein blood concentration or a
lesser affinity for iodothyronines, although without signifi-
cant clinical or laboratory changes in thyroid hormones
status.
Albumin
Familial dysalbuminemic hyperthyroxinemia (FDH) is
another cause of inherited euthyroid hyperthyroxinemia.
It results from albumin gene (4q13.3) mutations that
lead to an increased affinity for fT4 and is inherited as
an autosomal dominant disease. Although relatively rare,
FDH is the most prevalent cause of inherited euthyroid
hyperthyroxinemia in the Caucasian population (up to
12% of all cases, from 1:10,000 to 17:10,000) [40,41].
The following values are expected in laboratory tests:
normal TSH (also after TRH stimulation) fT4, fT3,
normal or slightly elevated T3, elevated T4, rT3 (in
some cases) and an increased proportion of T4 bound to
serum albumin (approximately four times higher than
normally) [42]. The diagnostic problem may be falsely
elevated fT4, as the laboratory techniques usually used
are not accurate enough in that case, which may lead to
unnecessary treatment [43]. In most cases, mutations at
position 218 of the amino acid chain are present.
However, another one was found in codon 66 (L66P)
and leads to an increased affinity for fT3 and hypertriio-
dothyroninemia (FDH-T3) [44].Thyroid hormone resistance (RTH)
Thyroid hormones act primarily via nuclear receptors
(TR): 1) TRα1 encoded by THRA (17q21.1) and 2) TRβ1
or TRβ2 encoded by THRB (3p24.2 ) (different expres-
sion pattern of both subtypes). T3 forms a complex with
TR, and subsequently binds to the promoter region of
the target genes (thyroid hormone response elements),
acting as a transcription factor.
Mutations in TR genes lead to thyroid hormone resist-
ance (RTH), disorder transmitted in the majority of
cases in an autosomal dominant manner. Although no
precise data are available, the prevalence is estimated to
be 1:40,000 newborns [45]. In approximately 85-90% of
RTH cases, the disease is caused by THRB mutations
that lead to a decreased affinity for T3 or impaired inter-
actions with TRβ cofactors. In these cases, elevated fT4
(often also fT3 and rT3) associated with normal or
elevated (non-suppressed) TSH level is observed [46].
As a consequence of the variable manifestations ob-
served among patients, RTH was formerly classified into
generalized, isolated peripheral and isolated pituitary
resistance. Often some evidence of both hyper- and
hypothyroidism can be found in one patient (goiter,
sinus tachycardia etc. may be associated with learning
disabilities and delayed growth or bone age). In rare
cases of homozygous THRB mutations, more severe
symptoms are observed with coexisting deaf-mutism
and color blindness [47].
Mutations in THRA were also described, which lead to
different symptoms and thyroid function test results
than in THRB defects. The symptoms of thyroid hormone
deficiency are restricted to those tissues in which TRα pre-
dominates (central nervous system, myocardium, striated
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[48]. Laboratory tests show a decreased fT4, very low rT3
and elevated fT3.
In a group of RTH patients (up to 15%), neither THRB
nor THRA gene mutations were found (non TR-RTH),
although phenotypically they may be indistinguishable
from those with TRβ alterations. This subtype is also
inherited in an autosomal dominant manner and ex-
pected to result from some TRβ cofactors mutations or
defects in receptor regulation, although undefined to
date [49].
Recently, the term ‘reduced sensitivity to thyroid hor-
mones’ (RSTH) was introduced, which encompasses RTH
and decreased responsiveness to thyroid hormones caused
by iodothyronine transmembrane transport defect (muta-
tions of MCT8 gene - SLC16A2 in Xq13.2) or T4 to T3
deiodination defect (mutations of SBP2 gene - SECISBP2
in 9q22.2) [50-52].
Rare causes of hyperthyroidism
Congenital hyperthyroidism, a generally rare disease
(overt hyperthyroidism in 1:50,000 newborns), is most
often transient and caused by the maternal thyroid
stimulating antibodies in the course of Graves’ disease,
subsequently transferred to fetal circulation (hyperthy-
roidism in 0.6-1% of offspring born to GD mothers)
[53]. However, in some neonates there are no thyroid
antibodies in serum, the mother’s disease is excluded
and hyperthyroidism is persistent. This may suggest a
condition called non-autoimmune hyperthyroidism
(NAH). NAH develops as a result of gain-of-function
germline mutation within the TSH receptor gene (TSHR),
leading to constitutive TSHR pathway activation. It can be
divided into sporadic (SNAH) and familial (FNAH) with
an autosomal dominant mode of inheritance [54,55]. To
date, at least 21 different mutations of TSHR in FNAH
and 12 in SNAH have been found. Similar mutations, but
of a somatic type, can be found in toxic thyroid nodules
[56]. Clinically, patients with NAH usually present with
goiter and hyperthyroidism. Moreover, pharmacologic
treatment may be ineffective (frequent relapses are ob-
served) and total thyroidectomy or complete radioiodine
ablation is usually necessary.
Hyperthyroidism is also observed in patients with
McCune-Albright syndrome (MAS), as a result of the
activating somatic mutation of the GNAS gene. As men-
tioned previously, GSα is a part of the TSHR signaling
cascade and its constitutive activation is followed by a
cAMP increase, which in turn results in thyrocyte
hyperproliferation and iodothyronine excess. GSα is
committed to extracellular signals transduction in
different tissues as well. As GNAS mutations occur in
MAS in the post-zygotic period and patients are mo-
saic, variable manifestations are observed. The classicaltriad of symptoms include bone fibrous dysplasia, café-
au-lait spots and hyperfunctional endocrinopathies
(most frequently peripheral precocious puberty, but
also hyperthyroidism, hypercortisolism, hypophyseal
hyperfunction and kidney phosphate wasting). MAS
prevalence range from 1:100,000 to 1:1,000,000 [57],
with functional or morphological changes in the thy-
roid in approximately 31% of cases [58].
Symptoms of hyperthyroidism may also be observed,
albeit rarely, in the course of struma ovari (5-15% of
cases), differentiated thyroid cancer (usually methastatic)
and an gestational trophoblastic disease [59-61]. Further-
more, central (secondary) hyperthyroidism due to TSH
secreting pituitary adenoma can be classified as a rare
disease as it accounts for only about 1% of all pituitary
adenomas (prevalence of 1:1,000,000) [62].
Rare thyroid inflammatory diseases
Thyroid gland tuberculosis is very rarely observed in the
course of generalized disease (even in regions with a
relatively high incidence of tuberculosis) and much less
frequently as a change isolated or primarily localized in
the thyroid. Analyses of surgically removed glands or
fine needle aspiration biopsy (FNAB) materials showed a
prevalence of 0.1-0.6% [63,64]. Thyroid tuberculosis may
present as a single nodule, multinodular goiter or
diffused swelling, it may be found as a cold abscess or
rarely an acute abscess [65]. Some patients remain
symptomless, while others develop dyspnea, dysphagia,
hoarseness, pain or tenderness. Typically, the hormonal
status of the thyroid gland is unaffected, although hyper-
thyroidism may occur in some cases, as a result of exces-
sive release of thyroid hormones from damaged tissue.
Hypothyroidism, which is extremely rarely observed, may
be caused by extensive tissue destruction [66]. To estab-
lish the diagnosis, ultrasound-guided FNAB should be
performed with Ziehl Neelsen staining, culture and cyto-
logical examination (caseating granulomas with epithelioid
cells and Langhans giant cells).
Sarcoidosis - a noncaseating granulomatous disorder,
may rarely affect the thyroid gland in the course of gen-
eralized disease. Usually, extrathyroidal manifestation of
the disease precedes the diagnosis of thyroid involve-
ment. Some rare cases of sarcoidosis limited to the thy-
roid gland can be also found in the literature [67]. In
post-mortem studies of patients with previously found
systemic sarcoidosis, the thyroid gland was affected in
up to 4.5% [68]. Thyroid sarcoidosis usually presents as
a progressive painless enlargement of the gland with un-
affected hormonal status, although different manifesta-
tions are possible (hyperthyroidism, hypothyroidism, acute
thyroiditis, multinodular goiter or solitary thyroid nodule,
it may sometimes be painful). Cases of hyperthyroidism
resistant to both pharmacological and radioiodine
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sarcoidosis, and in these cases surgical removal of the
gland is required. Studies also suggest an increased
prevalence of high antithyroid antibodies concentra-
tion and thyroid autoimmune diseases associated with
sarcoidosis, regardless of thyroid gland involvement
(an ATD frequency in patients with sarcoidosis 1.9-
16,6%) [69].
Conclusions
Most of the rare thyroid diseases presented in this paper
have a genetic origin, among them monogenic disorders
can be found. Progress in our understanding of their
etiology and pathogenesis has been observed in the past
years, what also shed new light on how the normal thy-
roid gland functions and the role of different proteins in
this process, although there are still some questions that
need answers. Secondly, rare thyroid diseases may be a
challenging problem for clinicians because of their rarity
and variability in manifestations. They should be kept in
mind as a differential diagnosis of other diseases more
commonly seen in clinical practice. A correct and unde-
layed diagnosis is especially important in the case of
congenital thyroid function disruptions, as untreated,
they may lead to serious consequences.
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